ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
SAN DIEGO (PRWEB) October 02, 2018 -- As a leading innovator in the development of tools for the cancer research laboratory, ACEA Biosciences, The Cell Analysis Company, is excited to offer xCELLigence® RTCA Software Pro, an integrated software package designed specifically for immuno-oncology applications. Experimental design and data analysis for immune oncology researchers are now much easier, especially when combined with the high throughput and label-free xCELLigence Real Time Cell Analysis (RTCA) platforms from ACEA Biosciences.
With this new software package, scientists can automatically measure cytolysis of target tumor cells by immune effector cells and other molecules to evaluate new cancer immunotherapies. xCELLigence RTCA Software Pro is ideal for immunotherapy studies including genetically engineered CAR-T cells, antibody-dependent cell-mediated cytotoxicity (ADCC), bispecific T cell engagers (BiTes), immune checkpoint inhibitors, NK cells and much more.
“With the promise of immunotherapies for treating cancer, the team at ACEA Biosciences wanted to develop effective software tools for this area of research. The clinical outcome of these therapies has been remarkable in terms of patient responses,” said Aimee Chiavario, Senior Marketing Manager for Immuno-Oncology Applications at ACEA Biosciences. “We are excited to help accelerate the timelines of our immunotherapy customers.”
Benefits of xCELLigence RTCA Software Pro include:
- Immunotherapy experiment specific functions – Users can accurately calculate % Cytolysis through the subtraction of effector background and the use of reference samples such as target tumor cells and mock effector cells. The software can also automatically determine kinetic parameters such as the time point for 50% tumor cell killing (KT50).
- Simple experimental set up – Target tumor cells, effector cells, and dose dependent treatments are easily recorded based on the experiment design and well content. The interactive software automatically recognizes control wells based on plot type selection and normalization.
- Improved user interface – With the updated 96 well plate map, target tumor cells, effector cells, or experimental drug dosages can be visualized individually or in combinations through a pie chart, enabling quick comparison between wells. Users can select and simultaneously display relevant data from specific wells. The combined plot and data analysis window provides a convenient way to demonstrate results.
About xCELLigence® Real Time Cell Analysis (RTCA)
ACEA’s xCELLigence RTCA instruments are being used in both academia and industry for life science applications ranging from cancer immunotherapy, bacterial biofilms, vaccine development and cardiotoxicity testing. With the xCELLigence technology, scientists can non-invasively monitor the behavior of cells by quantifying cell proliferation, morphology change, and attachment quality in a label-free, real-time manner.
About ACEA Biosciences
Founded in 2002, ACEA Biosciences is a pioneer in the development and commercialization of high performance cell analysis platforms for life science research. ACEA’s xCELLigence® Real-Time Cell Analysis instruments and NovoCyte® aQuanteon flow cytometers are used in pre-clinical drug discovery and development, toxicology, safety pharmacology, and basic academic research. More than 2,500 instruments have been placed globally, and have been used in more than 1,800 peer-reviewed publications.
For more information visit http://www.aceabio.com
Follow on LinkedIn, Twitter, and Facebook
For further information please contact:
ACEA Biosciences, Inc.
Dr. Jeff Xue
Phone: 858-299-8023
email: jxue(at)aceabio(dot)com
Jeff Xue, Ph.D., ACEA Biosciences, Inc., http://www.aceabio.com, +1 8587240928 Ext: 3075, [email protected]
Share this article